

# Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance

NCT05470504

---

Status	RECRUITING
Phase	Phase 2
Sponsor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Enrollment	25 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- To be eligible to participate in this study, an individual must meet all the following criteria:
  - Either
  - Known pathogenic variant in the insulin receptor gene, either dominant negative or recessive, OR
  - Clinical diagnosis of partial lipodystrophy based on reduction in adipose tissue outside the normal range in selected adipose depots (including, at a minimum, the gluteofemoral depot) with preservation of adipose tissue in other depots.
  - Male or female, aged 18-70 years.
- ... and 1 more (see full listing online)

### Exclusion (17)

- An individual who meets any of the following criteria will be excluded from participation in this study:
  - Use of niacin or other drugs that directly affect lipolysis within 8 weeks prior to enrollment.
  - Patients taking anticoagulants (blood thinning medications).
  - Use of non-steroidal anti-inflammatory medications (e.g., aspirin, ibuprofen) 2 weeks prior to the biopsy date (in patients who choose to undergo biopsy).
  - Changes in medications for diabetes or dyslipidemia within 2 weeks prior to enrollment.
- ... and 12 more (see full listing online)

## Locations (1 total)

---

National Institutes of Health Clinical Center, Bethesda, Maryland, United States